Dr Stephen Parker, aged 60, has a career in the healthcare and pharma sector that spans over 30 years, including six years in the City in advisory roles. He has sector corporate finance experience having been an investment banker focusing on pharma and biotechnology with Barings, Warburg and Apax Partners and has previously held roles as a partner at Celtic Pharma and Chief Financial Officer of Oxford GlycoSciences. Stephen is also a Non-executive Director at MGC Pharma.
Dr Tim Mitchell, aged 58, has a wide breadth of management, business and research expertise gained over 30 years in the biotech, large pharmaceutical and research service companies.
He is the inventor of Oblean® (cetilistat) for which Takeda have obtained sales approval in the Japanese market for the treatment of obesity with complications.
Prior to co-founding Sareum he was Director of Structure-Based Discovery at Millennium Pharmaceuticals, Director of Computational Chemistry at Cambridge Discovery Chemistry, and Team Leader at SmithKline Beecham Pharmaceuticals. Tim has a PhD in Computational Chemistry and a BSc in Chemistry.
Dr John Reader, aged 52, has over 25 years' experience within the industry. His previous roles include Associate Director, Chemical Technologies at Millennium Pharmaceuticals Research and Development Ltd, Pharmacopeia Inc., and Cambridge Discovery Chemistry.
John has an excellent track record of delivering successful drug research projects. He has authored or co-authored many publications and patents on small molecule drug discovery. John is a member of the EPSRC Peer Review College and has a PhD in Chemistry and a BSc in Applied Chemistry.
Dr Michael Owen, aged 67, has worked in biomedical research, and in the pharmaceutical and biotechnology industries for nearly 40 years. He is the co-founder and first CSO of Kymab Ltd, a biopharmaceutical company based in Cambridge, UK, prior to which he worked for GSK where he was SVP and Head of Research for Biopharmaceuticals R&D. Dr Owen currently serves on the boards of several public and private biotechnology companies in the UK, Europe and the USA, including Avacta Group plc, ReNeuron plc, GammaDelta Therapeutics and Zealand Pharma A/S. He is also the Chairman of Ossianix Inc. In addition, Dr Owen is Chairman of ReNeuron’s and Avacta’s scientific advisory boards, an advisor to Abingworth LLP and was until recently an advisor to the CRT Pioneer Fund. Dr Owen received a MA from Oxford University and a PhD from Cambridge University, and is an elected member of the European Molecular Biology Organisation and a Fellow of the Academy of Medical Sciences.
Clive Birch, aged 65, is an Independent Non-Executive Director of Cambridge Innovation Capital plc, a Cambridge-based builder of technology and healthcare companies. He is a retired partner of PricewaterhouseCoopers where his role was that of an auditor and reporting accountant with an industry specialism in early stage technology and healthcare companies. He was also part of the teams involved in fund raising and listing those clients on various markets. Mr Birch was also partner in charge of PwC’s Cambridge office for 15 years up to 2010, during which time he was responsible for all aspects of that stand-alone business. Mr Birch is a Governor of Birkbeck College, part of London University.
Dr Finch has many years’ experience in the Pharmaceutical industry and is currently Executive Vice President at Pulmagen Therapeutics. He was previously Executive VP of Argenta Discovery, a Director at RiboTargets and spent 24 years at GlaxoSmithKline and its predecessor companies, latterly as Director of Chemistry for UK Research & Development.
Harry has extensive experience in a wide range of therapeutic areas. He was a co-inventor of Salmeterol (Serevent; GSK), a successful long-acting bronchodilator for asthma and has 45 patents and 49 publications to his name.
Dr Jackson was formerly Chief Scientific Officer at the cancer drug discovery company, Cyclacel Limited. Prior to that, he held senior research positions at Celltech, Agouron, DuPont and Warner-Lambert. Dr Jackson has led teams that have developed 26 compounds to clinical trials, including the Aurora Kinase inhibitor CYC116, and gained his PhD in biochemistry from the University of London.